Katina Robison

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 376 citations · Full text

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass

Richard G. Moore, Moune Jabre-Raughley, Amy Brown et al. · American Journal of Obstetrics and Gynecology · 2010 · 353 citations · Full text

Gynecological Surgery, Cancer Detection, Malignancy Index +8

Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals

T. Febbraro, Katina Robison, Jennifer Scalia Wilbur et al. · Gynecologic Oncology · 2015 · 116 citations · Full text

Family Medicine, Adherence Patterns, Cancer Epidemiology +9

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

Martee L. Hensley, Danielle Enserro, Helen Hatcher et al. · Journal of Clinical Oncology · 2018 · 85 citations · Full text

Gender Differences in Scholarly Productivity Within Academic Gynecologic Oncology Departments

Emily K. Hill, Rachel A. Blake, Jenna Emerson et al. · Obstetrics and Gynecology · 2015 · 69 citations · Full text

Altmetrics, Academic Rank, Gender Disparity +14